CN114008027A - 二氨基嘧啶类化合物的盐、其固体形式及其制备方法和用途 - Google Patents

二氨基嘧啶类化合物的盐、其固体形式及其制备方法和用途 Download PDF

Info

Publication number
CN114008027A
CN114008027A CN202080032505.XA CN202080032505A CN114008027A CN 114008027 A CN114008027 A CN 114008027A CN 202080032505 A CN202080032505 A CN 202080032505A CN 114008027 A CN114008027 A CN 114008027A
Authority
CN
China
Prior art keywords
compound
acid
salt
diffraction angles
characteristic peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080032505.XA
Other languages
English (en)
Other versions
CN114008027B (zh
Inventor
赵焰平
王红军
冯泽旺
黄淮
刘凯
刘雪莲
庞建梅
田娜娜
陈玺朝
付深圳
孟杰
周丽莹
刘亚男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tide Pharmaceutical Co Ltd
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of CN114008027A publication Critical patent/CN114008027A/zh
Application granted granted Critical
Publication of CN114008027B publication Critical patent/CN114008027B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明涉及5‑((2‑乙炔基‑5‑异丙基吡啶‑4‑基)氧基)嘧啶‑2，4‑二胺的盐及其固体形式，制备所述固体形式的方法、包含所述固体形式的药物组合物，以及所述固体形式用于预防或治疗P2X3和/或P2X2/3受体拮抗剂调节的疾病的用途。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN202080032505.XA 2019-04-30 2020-04-29 二氨基嘧啶类化合物的盐、其固体形式及其制备方法和用途 Active CN114008027B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/085208 2019-04-30
CN2019085208 2019-04-30
PCT/CN2020/087688 WO2020221276A1 (zh) 2019-04-30 2020-04-29 二氨基嘧啶类化合物的盐、其固体形式及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN114008027A true CN114008027A (zh) 2022-02-01
CN114008027B CN114008027B (zh) 2024-02-20

Family

ID=73029675

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080032505.XA Active CN114008027B (zh) 2019-04-30 2020-04-29 二氨基嘧啶类化合物的盐、其固体形式及其制备方法和用途

Country Status (9)

Country Link
US (1) US20220177447A1 (zh)
EP (1) EP3964500A4 (zh)
JP (1) JP7553471B2 (zh)
KR (1) KR20220008285A (zh)
CN (1) CN114008027B (zh)
AU (1) AU2020266699A1 (zh)
CA (1) CA3138235A1 (zh)
TW (1) TWI761826B (zh)
WO (1) WO2020221276A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019085916A1 (zh) * 2017-11-01 2019-05-09 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途
EP3964505A4 (en) * 2019-04-30 2022-12-21 Beijing Tide Pharmaceutical Co., Ltd. SOLID FORM OF DIAMINOPYRIMIDINE COMPOUND OR A HYDRATE THEREOF, METHOD FOR PREPARING IT AND APPLICATION

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108834412A (zh) * 2016-03-14 2018-11-16 传入制药公司 嘧啶及其变体、及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6546592B2 (ja) * 2013-08-23 2019-07-17 アファレント ファーマシューティカルズ インコーポレイテッド 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター
WO2019085916A1 (zh) * 2017-11-01 2019-05-09 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途
EP3964505A4 (en) * 2019-04-30 2022-12-21 Beijing Tide Pharmaceutical Co., Ltd. SOLID FORM OF DIAMINOPYRIMIDINE COMPOUND OR A HYDRATE THEREOF, METHOD FOR PREPARING IT AND APPLICATION

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108834412A (zh) * 2016-03-14 2018-11-16 传入制药公司 嘧啶及其变体、及其用途

Also Published As

Publication number Publication date
WO2020221276A1 (zh) 2020-11-05
AU2020266699A1 (en) 2021-12-16
CA3138235A1 (en) 2020-11-05
EP3964500A4 (en) 2022-12-21
KR20220008285A (ko) 2022-01-20
US20220177447A1 (en) 2022-06-09
TW202106674A (zh) 2021-02-16
CN114008027B (zh) 2024-02-20
EP3964500A1 (en) 2022-03-09
JP2022531571A (ja) 2022-07-07
TWI761826B (zh) 2022-04-21
JP7553471B2 (ja) 2024-09-18

Similar Documents

Publication Publication Date Title
US10550101B2 (en) Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof
WO2022042712A1 (zh) Rho相关蛋白激酶抑制剂的盐、其固体形式及其制备方法和用途
CN114008027B (zh) 二氨基嘧啶类化合物的盐、其固体形式及其制备方法和用途
CN113993858B (zh) 二氨基嘧啶类化合物或其水合物的固体形式及其制备方法和用途
WO2023041026A1 (zh) Rho相关蛋白激酶抑制剂或其溶剂合物的固体形式及其制备方法和用途
CN107043368B (zh) 芳胺嘧啶化合物及其盐的结晶
WO2022268218A1 (zh) 一种杂环烷基类化合物的制备方法、其中间体及其应用
CN107382975B (zh) 氟代芳胺嘧啶化合物及其盐的结晶形式
EP3486243B1 (en) Benzimidazole derivatives as dual histamine h1 and histamine h4 receptor ligands
CN117986234A (zh) 芳基酰胺化合物及其盐的固体形式及其用途
CN112142730A (zh) 杂芳基并四氢吡啶类化合物的固体形式及其制备方法
CN117417327A (zh) Hcv抑制剂的盐、盐的晶型、其药物组合物及其用途
CN115702154A (zh) 一种嘧啶类化合物的盐和晶型及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063145

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant